Publication Name	World Journal of Virology
Manuscript ID	76337
Country	Bulgaria

Received	2022-03-13 00:44
Peer-Review Started	2022-03-13 00:46
To Make the First Decision
Return for Revision	2022-04-08 09:06
Revised	2022-05-14 13:01
Second Decision	2022-08-09 02:55
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-08-11 03:56
Articles in Press	2022-08-11 03:56
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-08-04 04:37
Typeset the Manuscript	2022-08-24 03:32
Publish the Manuscript Online	2022-09-24 10:56

ISSN	2220-3249 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Review
Article Title	Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic
Manuscript Source	Invited Manuscript
All Author List	Dimitrina Miteva, Monika Peshevska-Sekulovska, Violeta Snegarova, Hristiana Batselova, Radostina Alexandrova and Tsvetelina Velikova
Funding Agency and Grant Number	Funding Agency Grant Number None
Corresponding Author	Tsvetelina Velikova, MD, PhD, Assistant Professor, Department of Clinical Immunology, University Hospital Lozenetz, Kozyak 1 Street, Sofia 1407, Bulgaria. tsvelikova@medfac.mu-sofia.bg
Key Words	SARS-CoV-2; COVID-19 vaccine; Mucosal immunity; Intranasal vaccination; Oral vaccines; Resident memory T cells; Vaccine safety; Vaxart; OraPro-COVID-19 vaccine; RPS-vector system platform
Core Tip	Oral or nasal vaccination against coronavirus disease 2019 (COVID-19) would stimulate both the humoral and cellular immune responses and may exert many socioeconomic benefits. Mucosal vaccines are promising for preventing infections and reducing the transmission, morbidity and mortality of COVID-19. Mucosal vaccination may be used prophylactically in human populations at high risk for severe acute respiratory syndrome coronavirus 2. Currently, only a limited number of oral vaccines are approved for human use, and some others are included in preclinical and clinical trials to validate their efficacy and safety.
Publish Date	2022-09-24 10:56
Citation	Miteva D, Peshevska-Sekulovska M, Snegarova V, Batselova H, Alexandrova R, Velikova T. Mucosal COVID-19 vaccines: Risks, benefits and control of the pandemic. World J Virol 2022; 11(5): 221-236
URL	https://www.wjgnet.com/2220-3249/full/v11/i5/221.htm
DOI	https://dx.doi.org/10.5501/wjv.v11.i5.221

Full Article (PDF)	WJV-11-221.pdf
Full Article (Word)	WJV-11-221.docx
Manuscript File	76337_Auto_Edited-LM.docx
Answering Reviewers	76337-Answering reviewers.pdf
Audio Core Tip	76337-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	76337-Conflict-of-interest statement.pdf
Copyright License Agreement	76337-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	76337-Language certificate.pdf
Peer-review Report	76337-Peer-review(s).pdf
Scientific Misconduct Check	76337-Bing-Liu JH-2.jpg
Scientific Misconduct Check	76337-CrossCheck.jpg
Scientific Editor Work List	76337-Scientific editor work list.pdf